QQ客服 官方微博 反馈留言

	Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China
	Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiaoe; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu
刊名	DIABETES-METABOLISM RESEARCH AND REVIEWS
	2017
卷号	33
ISSN号	1520-7560
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3540133
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Zhu, Dalong,Gan, Shenglian,Liu, Yu,et al. Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China[J]. DIABETES-METABOLISM RESEARCH AND REVIEWS,2017,33.
APA	Zhu, Dalong.,Gan, Shenglian.,Liu, Yu.,Ma, Jianhua.,Dong, Xiaolin.,...&Chen, Li.(2017).Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China.DIABETES-METABOLISM RESEARCH AND REVIEWS,33.
MLA	Zhu, Dalong,et al."Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China".DIABETES-METABOLISM RESEARCH AND REVIEWS 33(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。